Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aveo Pharmaceuticals (AVEO)

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aveo Pharmaceuticals 30 WINTER STREET BOSTON MA 02108 USA

P: 857-400-0101

Description:

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 521,445
Enterprise Value, $K 472,085
Shares Outstanding, K 34,763
Annual Sales, $ 42,300 K
Annual Net Income, $ -53,340 K
Last Quarter Sales, $ 30,450 K
Last Quarter Net Income, $ -3,270 K
60-Month Beta 1.00
% of Insider Shareholders 3.29%
% of Institutional Shareholders 49.95%
Float, K 33,619
% Float 96.71%
Short Volume Ratio 0.15

Growth:

1-Year Return 302.14%
3-Year Return 153.81%
5-Year Return -50.33%
5-Year Revenue Growth 1,578.57%
5-Year Earnings Growth 61.86%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.09 on 11/07/22
Next Earnings Date 03/13/23
Earnings Per Share ttm -0.84
EPS Growth vs. Prev Qtr 62.50%
EPS Growth vs. Prev Year 70.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 02/20/20

AVEO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 23.81
Price/Earnings to Growth N/A
Return-on-Equity % -81.66%
Return-on-Assets % -28.83%
Profit Margin % -126.10
Net Margin % 28.43
Debt/Equity 0.94
Price/Sales 5.49
Price/Cash Flow N/A
Price/Book 18.00
Book Value/Share 0.83
Interest Coverage -12.17
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar